Ellagic acid supplementation in patients with non-alcoholic fatty liver disease

Phase 3

Recruiting

• Conditions: K75.8; on alcoholic fatty liver disease.; Other specified inflammatory liver diseases

• Registration Number: IRCT20141025019669N21
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

18-55 years old patient with non-alcoholic fatty liver,
confirmation of non-alcoholic fatty liver with liver ultrasound
Having a body mass index of less than 30
A consent signed by the patient.

Exclusion Criteria

Pregnancy and lactation
Infectious disease, inflammatory disease, Cushing's syndrome, adrenal gland tumor, hypothyroidism, diabetes, and cancer.
Taking antioxidant supplements in the last three months
Taking medication in the last three months including glucocorticoids drugs, lipid-lowering drugs, and weight-loss drugs.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Liver enzymes. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Adiponectin hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.